1 Pain on weight bearing (0‐100 mm VAS) |
27 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
1.1 1 to 4 weeks post‐injection |
27 |
2542 |
Mean Difference (IV, Random, 95% CI) |
‐7.70 [‐11.29, ‐4.10] |
1.2 5 to 13 weeks post‐injection |
21 |
2090 |
Mean Difference (IV, Random, 95% CI) |
‐11.00 [‐17.77, ‐8.23] |
1.3 14 to 26 weeks post‐injection |
10 |
1491 |
Mean Difference (IV, Random, 95% CI) |
‐9.04 [‐14.83, ‐3.24] |
1.4 45 to 52 weeks post‐injection |
3 |
527 |
Mean Difference (IV, Random, 95% CI) |
‐2.60 [‐7.40, 2.19] |
2 Pain at rest (0‐100 mm VAS) |
12 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
2.1 1 to 4 weeks post‐injection |
12 |
577 |
Mean Difference (IV, Random, 95% CI) |
‐5.37 [‐9.90, ‐0.85] |
3 WOMAC pain |
9 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
3.1 1 to 4 weeks post‐injection |
7 |
412 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.22 [‐1.93, ‐0.52] |
3.2 5 to 13 weeks post‐injection |
7 |
639 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.02 [‐1.57, ‐0.47] |
3.3 14 to 26 weeks post‐injection |
4 |
275 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.04 [‐1.75, ‐0.32] |
4 WOMAC physical function |
9 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
4.1 1 to 4 weeks post‐injection |
7 |
412 |
Std. Mean Difference (IV, Random, 95% CI) |
‐1.02 [‐1.62, ‐0.42] |
4.2 5 to 13 weeks post‐injection |
7 |
639 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.85 [‐1.31, ‐0.39] |
4.3 14 to 26 weeks post‐injection |
4 |
275 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.80 [‐1.37, ‐0.24] |
5 Lequesne Index (0‐24) |
11 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
5.1 1 to 4 weeks post‐injection |
7 |
495 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.82 [‐1.48, ‐0.16] |
5.2 5 to 13 weeks post‐injection |
7 |
506 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.38 [‐2.04, ‐0.73] |
5.3 14 to 26 weeks post‐injection |
4 |
566 |
Mean Difference (IV, Fixed, 95% CI) |
0.06 [‐0.75, 0.87] |
5.4 45 to 52 weeks post‐injection |
1 |
94 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.11 [‐2.70, 0.48] |
6 Patient global assessment (number of patients improved) |
14 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
6.1 1 to 4 weeks post‐injection (much better/better or excellent/good) |
6 |
594 |
Risk Ratio (M‐H, Random, 95% CI) |
1.10 [0.89, 1.36] |
6.2 5 to 13 weeks post‐injection (excellent/very good/good/better/somewhat better) |
6 |
579 |
Risk Ratio (M‐H, Random, 95% CI) |
1.09 [0.87, 1.37] |
6.3 14 to 26 weeks post‐injection (better/somewhat/much) |
4 |
552 |
Risk Ratio (M‐H, Random, 95% CI) |
1.04 [0.73, 1.47] |
6.4 45 to 52 weeks post‐injection (number of patients rating treatment effective or very good or good) |
2 |
290 |
Risk Ratio (M‐H, Random, 95% CI) |
1.01 [0.82, 1.23] |
7 Flexion (degrees) |
3 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
7.1 1 to 4 weeks post‐injection |
3 |
174 |
Mean Difference (IV, Fixed, 95% CI) |
3.87 [2.06, 5.68] |
7.2 5 to 13 weeks post‐injection |
1 |
35 |
Mean Difference (IV, Fixed, 95% CI) |
7.60 [0.46, 14.74] |
8 Safety: total withdrawals overall |
25 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
8.1 1 to 4 weeks post‐injection |
5 |
525 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.61, 2.15] |
8.2 5 to 13 weeks post‐injection |
8 |
858 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.11 [0.73, 1.67] |
8.3 14 to 26 weeks post‐injection |
9 |
1489 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.83, 1.20] |
8.4 45 to 52 weeks post‐injection |
3 |
389 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.14 [0.63, 2.08] |
9 Safety: number of patients with local adverse reaction and study drug discontinued |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
10 Safety: number of patients with local adverse reaction but study drug continued |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
11 Safety: number of patients discontinued due to adverse events |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
11.1 14 to 26 weeks post‐injection |
3 |
687 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.42 [0.69, 2.93] |
11.2 45 to 52 weeks post‐injection |
1 |
216 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [0.24, 6.93] |
12 Safety: withdrawals due to lack of efficacy |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
12.1 1 to 4 weeks post‐injection |
1 |
41 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
12.2 14 to 26 weeks post‐injection |
4 |
1005 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.63, 1.40] |
12.3 45 to 52 weeks post‐injection |
1 |
216 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.32 [0.03, 3.52] |
13 Safety: number of adverse events for injection site pain |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
13.1 14 to 26 weeks post‐injection |
2 |
381 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.70 [1.19, 2.44] |
14 Safety: number of adverse events local skin rash |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
14.1 14 to 26 weeks post‐injection |
2 |
558 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.55, 1.43] |
15 Safety: number of patients with gastrointestinal complaints |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
15.1 14 to 26 weeks post‐injection |
2 |
558 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.42 [0.99, 2.03] |
16 Safety: number of patients with treatment related adverse events |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
16.1 14 to 26 weeks post‐injection |
4 |
464 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.48 [0.91, 2.41] |
17 Safety: number of patients with possible study medication related events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
17.1 45 to 52 weeks post‐injection |
1 |
63 |
Risk Ratio (M‐H, Fixed, 95% CI) |
7.68 [0.41, 142.77] |
18 Safety: number of serious adverse events |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
18.1 45 to 52 weeks post‐injection |
2 |
392 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.60 [0.34, 1.07] |
19 Safety: number of adverse events probably or possibly related to treatment |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
19.1 45 to 52 weeks post‐injection |
2 |
392 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.49 [0.11, 2.20] |
20 Safety: number of patients reporting adverse events |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
20.1 45 to 52 weeks post‐injection |
2 |
308 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.91, 1.39] |